‹ BackHN Continuity

Thread

Claude discovers a novel enzyme system with CRISPR-like repeats

780 points · 805 comments · raahelb

  1. ryanschaefer · · focus · HN ↗
    I’m confused why AI companies are using agents in-house for this type of research instead of partnering externally.

    I guess the improvement loop is tighter and they have more control over how discoveries can be used for marketing?

    But, in my mind, it begins to feel like they are setting themselves up to be “everything” companies instead of focusing on their core product…

    1. consumer451 · · focus · HN ↗
      > I’m confused why AI companies are using agents in-house for this type of research instead of partnering externally.

      As an outsider, here is how I explain that behavior:

      1. Truly risky models are very useful.

      2. Truly risky models should not be released, according to AI safety standards. I think Antrhopic genuinely believes in AI safety. (see: standing up against automated kill chains, no matter the impacts to the company)

      3. Truly risky models face regulatory pressures, if released to the public.

      This all leads to "let's just do this in-house." I believe that might end up being the answer to every application of AI eventually. It seems unavoidable, and very depressing.

Open on Hacker News to reply ↗

Unofficial Hacker News client; not affiliated with Y Combinator.